deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT04224571

CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children

Chinese Children Cancer Group Relapsed Acute Lymphoblastic Leukemia 2017 Study

Sponsor: Chinese University of Hong Kong

Conditions Acute Lymphoblastic Leukemia, in Relapse
Interventions Bortezomib Injection rituximab injection
Updated 7 times since 2020 Last updated: Aug 29, 2023 Started: Sep 14, 2018 Primary completion: Feb 15, 2023 Completion: Feb 15, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Acute Lymphoblastic Leukemia, in Relapse, this trial is completed. The trial is conducted by Chinese University of Hong Kong and has accumulated 7 data snapshots since 2018. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshotRecruiting~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshotRecruiting~Mar 2021 – ~Sep 2022 · 18 months · monthly snapshotRecruiting~Sep 2022 – ~Sep 2023 · 12 months · monthly snapshotRecruiting~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 20 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Sep 2023 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

  4. Sep 2022 — Sep 2023 [monthly]

    Recruiting PHASE2

  5. Mar 2021 — Sep 2022 [monthly]

    Recruiting PHASE2

▶ Show 2 earlier versions

  1. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE2

  2. Feb 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

    First recorded

Sep 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Chinese University of Hong Kong
  • Shanghai Children's Medical Center
Data source: Chinese University of Hong Kong

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations